Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: a Brazilian public health care system perspective by Daniela Dornelles Rosa, Carlos Alberto da Silva Magliano, Sergio D. Simon, Gilberto Amorim, Tomás Reinert, Luciana Landeiro, Débora de Melo Gagliato, Pedro Exman, Daniel Argolo, Gisah Guilgen, Max Mano, Laura Testa, Pedro Liedke, Romualdo Barroso, Mariana Sasse, Anna Maria Buehler

Get full text